MRNA - Celsion adds Moderna chief commercial officer as CEO

• Clinical-stage biotech Celsion Corporation ( NASDAQ: CLSN ) announced on Tuesday that the company appointed Corinne Le Goff as its President and Chief Executive Officer effective July 18, 2022.
• Prior to joining Celsion ( CLSN ), Dr. Corinne served as the Chief Commercial Officer of Moderna ( MRNA ), spearheading the company’s efforts to ensure the global distribution of its blockbuster COVID-19 vaccine.
• She joined Moderna ( MRNA ) from pharma giant Amgen ( AMGN ) where she functioned as the President of its U.S. business.
• Despite the appointment of Dr. Corinne, former President and CEO Michael H. Tardugno will continue to serve Celsion’s ( CLSN ) board as the Executive Chairman.
• “Corinne’s skills and expertise in development and commercialization of therapeutics in oncology and immunology make her uniquely qualified to lead us on the next stage of growth,” Tardugno noted.

For further details see: